Rob Volansky

WASHINGTON — The novel CD40L inhibitor dapirolizumab pegol bested placebo in multiple systemic lupus erythematosus outcomes, including disease

WASHINGTON — Patients with autoimmune rheumatic diseases who withhold methotrexate for 2 weeks after receiving the recombinant herpes zoster vaccine

WASHINGTON — Alaska Native and American Indian populations demonstrate notably higher prevalences of ANCA-associated vasculitis vs. white patients, according to data presented at ACR Convergence 2024.

WASHINGTON — Severe acute COVID-19 infection, as well as glucocorticoid and rituximab use, increase the risk for long COVID in patients with autoimmune rheumatic diseases, according to data presented at ACR Convergence 2024.

WASHINGTON — Patients in early rheumatoid arthritis respond well to either abatacept or adalimumab, with the critical factor for both treatments being prompt initiation, according to data presented at ACR Convergence 2024.

WASHINGTON — An early, 1-year course of methotrexate may prevent anti-citrullinated protein autoantibody-negative rheumatoid arthritis in high-risk

WASHINGTON — Delaying methotrexate initiation for 1 month after pneumococcal vaccination improves humoral response in patients with rheumatoid arthritis, according to data presented at ACR Convergence 2024.

WASHINGTON — Chimeric antigen receptor nature-killing cell therapy achieved “efficacy, persistence and super safety” in a small cohort of patients

Clinical trial results in Sjögren's disease over the last decade have volleyed between encouraging successes and deflating failures, but with several new drugs advancing through the pipeline, hopes are high yet again.

The field of rheumatology has “left behind” patients with lupus from Africa — and across the global African diaspora — at nearly all academic and